Year :
2020
| Month :
August
| Volume :
14
| Issue :
8
| Page :
BC14 - BC17
Full Version
Assessment of Relationship between Galectin-3 and Biochemical Parameters in Peritoneal Dialysis Patients with Left Ventricular Hypertrophy
Published: August 1, 2020 | DOI: https://doi.org/10.7860/JCDR/2020/44534.13933
Sultan Alouffi, Ahmed Alsalloom, Menawer Alharbi, Wajid Khan, Waleed Tamimi
1. Associate Professor, Department of Clinical Laboratory Sciences, University of Hail, Hail, Saudi Arabia.
2. Consultant Nephrologist, Department of Nephrology, King Fahad Specialist Hospital, Buraidah, Qassim, Saudi Arabia.
3. Lab Specialist, Department of Laboratory Medicine and Central Blood Bank, King Fahad Specialist Hospital, Buraidah, Qassim, Saudi Arabia.
4. Associate Professor, Department of Chemistry, College of Sciences, University of Hail, Hail, Saudi Arabia.
5. Associate Professor, Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Correspondence Address :
Dr. Sultan Alouffi,
University of Hail, Hail, Saudi Arabia.
E-mail: s.alouffi@uoh.edu.sa
Abstract
Introduction: Cardiovascular complications are considered as the main cause of mortality in patients with End-Stage Renal Disease (ESRD). Cardiovascular Disease (CVD) includes disorders of the Left Ventricular Hypertrophy (LVH) of the heart which is the most frequent cardiac alteration in ESRD. Galectin-3 (GAL-3), a ß-galactoside-binding protein has been proposed to be a new clinical biomarker that reflects cardiac fibrosis in patients with Heart Failure (HF).
Aim: To evaluate the relationship between GAL-3 and biochemical parameters in Peritoneal Dialysis (PD) patients with and without LVH.
Materials and Methods: This cross-sectional study enrolled 45 patients (25 women and 20 men) with ESRD who were categorised as having CVD with (n=12) or without (n=33) LVH. Demographic, biochemical and clinical characteristics of 45 patients were analysed. The relationship of plasma GAL-3 levels was analysed with the biochemical parameters for both the groups of patients. For comparison between groups, Student unpaired t-test was used for the data of normal distribution while Mann-Whitney test was used for data of non-Gaussian distribution. Pearson’s correlation test was performed to examine various correlations.
Results: Significantly high number (83.3%) of female patients were observed in ESRD with LVH. The groups did not differ significantly in their demographic, and biochemical and clinical parameters. There was significant increase in Left Ventricular End-Diastolic Diameters (LVEDD), Left Ventricular (LV) mass and LV mass index in patients with LVH as compared to the patients without LVH. The levels of GAL-3 showed slight increase (91±23.98 ng/mL) levels in LVH patients as compared to the patients without LVH (83.68±32.8 ng/mL). Exponential positive correlation between serum levels of GAL-3 and creatinine in ESRD patients without LVH (r=0.563, p=0.001). GAL-3 also showed positive correlations with urea without (r=0.563, p=0.001) as well as and uric acid (r=0.416, p=0.0178) for ESRD patients without LVH. However, GAL-3 showed no association with uric acid and urea (r=0.04487, p=0.896; r=0.2383, p=0.48) in ESRD patients with LVH.
Conclusion: GAL-3 positively correlated to the biochemical parameters in ESRD patients. Patients with LVH only showed positive correlation between GAL-3 and creatinine. Moreover, GAL-3 could not be used as the biomarker because it did not correlate with established diagnostic parameter like LV mass and LV mass index. Hence, in this study GAL-3 is not a potential clinical biomarker for the progression of cardiovascular complications in ESRD patients. Overall, these data reflect the need for further investigation of GAL-3 to HF in patients with ESRD.
Keywords
Cardiovascular disease, Chronic kidney disease, End stage renal disease, Heart failure
DOI: 10.7860/JCDR/2020/44534.13933
Date of Submission: Apr 05, 2020
Date of Peer Review: Apr 27, 2020
Date of Acceptance: May 25, 2020
Date of Publishing: Aug 01, 2020
AUTHOR DECLARATION:
• Financial or Other Competing Interests: As declared above
• Was Ethics Committee Approval obtained for this study? Yes
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. NA
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Apr 06, 2020
• Manual Googling: May 19, 2020
• iThenticate Software: Jul 28, 2020 (15%)
ETYMOLOGY: Author Origin
|